WHO Model Prescribing Information: Drugs Used in Skin Diseases
(1997; 132 pages) [French] [Spanish] Voir le document au format PDF
Table des matières
Afficher le documentPreface
Afficher le documentIntroduction
Ouvrir ce répertoire et afficher son contenuParasitic infections
Ouvrir ce répertoire et afficher son contenuInsect and arachnid bites and stings
Ouvrir ce répertoire et afficher son contenuSuperficial fungal infections
Ouvrir ce répertoire et afficher son contenuSubcutaneous fungal infections
Ouvrir ce répertoire et afficher son contenuBacterial infections
Ouvrir ce répertoire et afficher son contenuViral infections
Ouvrir ce répertoire et afficher son contenuEczematous diseases
Ouvrir ce répertoire et afficher son contenuScaling diseases
Ouvrir ce répertoire et afficher son contenuPapulosquamous diseases
Afficher le documentCutaneous reactions to drugs
Ouvrir ce répertoire et afficher son contenuPigmentary disorders
Ouvrir ce répertoire et afficher son contenuPremalignant lesions and malignant tumours
Ouvrir ce répertoire et afficher son contenuPhotodermatoses
Ouvrir ce répertoire et afficher son contenuBullous dermatoses
Afficher le documentAlopecia areata
Afficher le documentUrticaria
Ouvrir ce répertoire et afficher son contenuConditions common in children
Afficher le documentAcne vulgaris
Afficher le documentPruritus
Afficher le documentTropical ulcers
Ouvrir ce répertoire et afficher son contenuAntimicrobial drugs
Ouvrir ce répertoire et afficher son contenuAntifugal drugs
Ouvrir ce répertoire et afficher son contenuAntiseptic agents
Fermer ce répertoireKeratoplastic and keratolytic agents
Afficher le documentBenzoyl peroxide
Afficher le documentCoal tar
Afficher le documentDithranol
Afficher le documentSalicylic acid
Afficher le documentTretinoin
Ouvrir ce répertoire et afficher son contenuScabicides and pediculicides
Ouvrir ce répertoire et afficher son contenuAnti-inflammatory and antipruritic drugs1
Ouvrir ce répertoire et afficher son contenuAntiallergics and drugs used in anaphylaxis
Ouvrir ce répertoire et afficher son contenuUltraviolet radiation-blocking agents (sunscreens)
Ouvrir ce répertoire et afficher son contenuMiscellaneous drugs
Ouvrir ce répertoire et afficher son contenuAnnex
Afficher le documentSelected WHO Publications of Related Interest
Afficher le documentBack cover
 

Coal tar

Solution, 5-10%
Ointment (crude coal tar), 1%

General information

Coal tar is a keratolytic agent that inhibits excessive proliferation of epidermal cells by reducing DNA synthesis and mitotic activity to normal levels.

Coal tar is not significantly absorbed following topical application.

Clinical information

Uses

Treatment of chronic psoriasis, either alone or in combination with exposure to ultraviolet light.

Dosage and administration

Adults and children: 100 ml of solution should be thoroughly mixed with bath water and the patient should soak for 10-20 minutes. Treatment may be repeated daily until the lesions have resolved.

Alternatively, a thin layer of ointment is applied to the affected areas once daily until the lesions have resolved.

Phototherapy should not be started until at least 24 hours after treatment and until all traces of the coal tar preparation have been removed from the skin.

Contraindications

Known hypersensitivity to tar preparations.

Precautions

Coal tar preparations should not be applied to inflamed, broken or infected skin.

Exposure to direct sunlight should be avoided as far as possible for at least 24 hours after treatment, because of the risk of photosensitivity reactions.

Although coal tar is a potential carcinogen, there is no evidence that it increases the risk of skin cancer at the doses used therapeutically.

Use in pregnancy

Safe use in pregnancy has not been demonstrated. Treatment should be deferred until after delivery whenever possible.

Adverse effects

Coal tar preparations cause skin irritation. Rarely, allergic sensitization occurs.

Photosensitivity reactions may occur, particularly when other photosensitizing agents are used.

Patients should be warned that staining of the skin and hair may occur.

Storage

Preparations should be stored in tightly closed containers, protected from light. They should not be allowed to freeze.

vers la section précédente
vers la section suivante
 
 
Le Portail d'information - Médicaments essentiels et produits de santé a été conçu et est maintenu par l'ONG Human Info. Dernière mise à jour: le 1 décembre 2019